Barbara Sennino

Title: Barbara Sennino: Innovator in Cancer Treatment

Introduction

Barbara Sennino is a prominent inventor based in San Francisco, CA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic antibodies. With a total of 8 patents, her work has the potential to impact the lives of many patients battling cancer.

Latest Patents

Sennino's latest patents include groundbreaking work on CD80 extracellular domain polypeptides and their use in cancer treatment. This patent provides antibodies and antigen-binding fragments that specifically bind to human B7-H4, which is crucial for enhancing T cell proliferation and increasing interferon-gamma production. Additionally, her research outlines methods for treating disorders, such as cancer, by administering these specific antibodies. Another notable patent involves the development of antigenic peptide-MHC complexes, termed comPACT polypeptides and polynucleotides, which are designed to capture cancer neoepitope-reactive T cells with high accuracy.

Career Highlights

Throughout her career, Barbara Sennino has worked with notable companies such as Five Prime Therapeutics, Inc. and Adoc Ssf, LLC. Her expertise in the field of immunology and cancer research has positioned her as a leader in developing innovative therapeutic solutions.

Collaborations

Sennino has collaborated with esteemed colleagues, including Thomas Brennan and Stefanie Mandl-Cashman. These partnerships have further enhanced her research and contributed to the advancement of cancer treatment methodologies.

Conclusion

Barbara Sennino's contributions to cancer treatment through her innovative patents and collaborations highlight her as a key figure in the field. Her work continues to pave the way for new therapeutic approaches that may significantly improve patient outcomes.